Skip to content
Home/Companies/Biotech/AptaTargets

AptaTargets

Biotech·Spain·Exited 2024·Held 7yr
Entry
2017
Hold
7yr
Exit
2024

Who owns AptaTargets?

AptaTargets was owned by Inveready Asset Management through Inveready Biotech II (2015 vintage) from 2017 to 2024, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-10

Inveready Asset Management
Investor
Inveready Asset Management
Inveready Biotech II · 2015 · Life Sciences VC

Key facts

HQSpain
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2024

More from Inveready Biotech II

Other portfolio companies in the same fund.

Medibiofarma
Medibiofarma
Active
BiotechSpain· 2019
Spiral Therapeutics
Spiral Therapeutics
Active
BiotechUnited States· 2019
VIVEbiotech
VIVEbiotech
Active
BiotechSpain· 2019
AntalGenics
AntalGenics
Active
BiotechSpain· 2017
BDI Biotech
BDI Biotech
Active
BiotechSpain· 2017
Edesa Biotech
Exited 2019
BiotechCanada· 2017

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track AptaTargets

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on AptaTargets.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue